Abstract
Abstract
Background/Objectives
DRAKO (NCT02850263) was a 24-month, prospective, non-interventional, multi-centre cohort study enrolling patients with diabetic macular oedema (DMO) including central involvement. The study evaluated UK standard-of-care intravitreal aflibercept (IVT-AFL) treatment. This analysis describes the treatment pathway and service provision for the anti–vascular endothelial growth factor (VEGF) treatment-naïve (C1) and non-naïve patients (C2) who received prior anti-VEGF treatment for DMO other than IVT-AFL.
Methods
Mean changes in best-corrected visual acuity and central subfield thickness were measured and stratified by baseline factors, including ethnicity and administration of five initial monthly injections within predefined windows. Clinic visits were classified as treatment only (T1), monitoring assessment only (T2), combined visits (T3) or post-injection visits with no treatment or assessment (T4).
Results
Median time from decision to treat to treatment was 6 days. As a percentage of total visits, T1, T2, T3 and T4 were 7%, 42%, 48% and 3% for C1 and 11%, 39%, 48% and 2% for C2. Most IVT-AFL injections were administered by healthcare professionals (HCPs) other than doctors (C1, 57.4%; C2, 58.5%). The percentage of treatments associated with a procedure-related adverse event where at least 75% of injections were completed by the same injector role were similar for doctors and other HCPs (C1, 1.1% and 0.8%; C2, 0.7%, and 1.0%).
Conclusions
Results indicate that upon DMO diagnosis, patients were treated promptly, and most visits were combined (treatment and assessment) or monitoring only. Most IVT-AFL was administered by non-physicians with a similar treatment-related safety profile as IVT-AFL administered by physicians.
Funder
This study was sponsored by Bayer Plc, Reading.
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. International Diabetes Federation Diabetes Atlas ninth edition. 2019. https://diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf
2. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;7:855–62.
3. NHS Diabetes Prevention Programme. 2022. https://www.england.nhs.uk/diabetes/diabetes-prevention/
4. National Institute for Health and Care Excellence. National strategy and policy to prevent type 2 diabetes. 2021. https://pathways.nice.org.uk/pathways/preventing-type-2-diabetes/national-strategy-and-policy-to-prevent-type-2-diabetes.
5. Diabetes UK. Diabetes diagnoses double in the last 15 years. 2021. https://www.diabetes.org.uk/about_us/news/diabetes-diagnoses-doubled-prevalence-2021